Chinese biopharma firm EOC Pharma snags $71m in Series C round

Chinese biopharma firm EOC Pharma snags $71m in Series C round

EOC has developed a pipeline of flagship products for oncology therapy.

02 December, 2019

EOC Pharma Sequoia Capital China Shionogi Tigermed

Printed by Unregistered user on Mon, 08 Dec 2025 07:25:07 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Venture Capital

China: Sequoia backs $32m Series B round in EOC Pharma

Venture Capital

Tencent leads $142m Series D+ round in Chinese oncology database Medbanks

Read more from Greater China

Asia Digest: OpenAI-backer Boman wins China licence; Ares buys majority stake in Aussie firm

Policy & Regulations

China proposes sweeping new rules to tighten listed company oversight